Joanna Gdula-Argasińska1, Jacek Czepiel2, Aneta Woźniakiewicz3, Katarzyna Wojtoń4, Agata Grzywacz5, Michał Woźniakiewicz3, Artur Jurczyszyn6, William Perucki7, Tadeusz Librowski4. 1. Department of Radioligands, Jagiellonian University Medical College, Faculty of Pharmacy, Kraków, Poland. Electronic address: jargasinska@cm-uj.krakow.pl. 2. Department of Infectious Diseases, Jagiellonian University Medical College, Faculty of Medicine, Kraków, Poland. 3. Laboratory of Forensic Chemistry, Jagiellonian University, Faculty of Chemistry, Kraków, Poland. 4. Department of Radioligands, Jagiellonian University Medical College, Faculty of Pharmacy, Kraków, Poland. 5. Department of Inorganic Chemistry, Jagiellonian University Medical College, Faculty of Pharmacy, Kraków, Poland. 6. Department of Hematology, University Hospital, Kraków, Poland. 7. Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA.
Abstract
BACKGROUND: Fatty acids and their derivatives are one of the most crucial inflammation mediators. The aim of our study was to evaluate the impact of polyunsaturated fatty acids as eicosanoids precursors on the A549 cell line. METHODS: Cells were incubated with 40 μM of arachidonic, eicosapentaenoic or docosahexaenoic acid for 24h, then activated with LPS. Fatty acids content in the cell membranes were determined using gas chromatography. COX-2, cPGES and FP-receptor quantities were determined by Western blot. 8-Isoprostane F2α concentrations were determined by EIA. Maresin and protectin D1 contents were analyzed by UHPLC/MS-TOF method. RESULTS: Significant differences in membrane fatty acids and levels of 8-isoPGF2α in the activated cells were detected. Elevated expression of COX-2 and FP-receptor was observed in cells treated with AA and activated with LPS. Moreover, compared to AA and AA+LPS groups, cells incubated with EPA, DHA, EPA+LPS and DHA+LPS showed decreased expression of COX-2, cPGES and FP-receptor. In cells incubated with EPA or DHA and activated with LPS maresin and protectin D1 were detected. CONCLUSIONS: The results of the study have revealed the pro-inflammatory properties of AA, while the EPA and DHA had the opposite, resolving effect. Interestingly, FP-receptor inhibition by EPA and DHA demonstrated the unique role of the FP-receptor as a potential target for antagonists, in the diseases of inflammatory character. This study provides new information about n-3 fatty acids and their pro-resolving mediators, which can be used in the process of developing new anti-inflammatory drugs.
BACKGROUND:Fatty acids and their derivatives are one of the most crucial inflammation mediators. The aim of our study was to evaluate the impact of polyunsaturated fatty acids as eicosanoids precursors on the A549 cell line. METHODS: Cells were incubated with 40 μM of arachidonic, eicosapentaenoic or docosahexaenoic acid for 24h, then activated with LPS. Fatty acids content in the cell membranes were determined using gas chromatography. COX-2, cPGES and FP-receptor quantities were determined by Western blot. 8-Isoprostane F2α concentrations were determined by EIA. Maresin and protectin D1 contents were analyzed by UHPLC/MS-TOF method. RESULTS: Significant differences in membrane fatty acids and levels of 8-isoPGF2α in the activated cells were detected. Elevated expression of COX-2 and FP-receptor was observed in cells treated with AA and activated with LPS. Moreover, compared to AA and AA+LPS groups, cells incubated with EPA, DHA, EPA+LPS and DHA+LPS showed decreased expression of COX-2, cPGES and FP-receptor. In cells incubated with EPA or DHA and activated with LPS maresin and protectin D1 were detected. CONCLUSIONS: The results of the study have revealed the pro-inflammatory properties of AA, while the EPA and DHA had the opposite, resolving effect. Interestingly, FP-receptor inhibition by EPA and DHA demonstrated the unique role of the FP-receptor as a potential target for antagonists, in the diseases of inflammatory character. This study provides new information about n-3 fatty acids and their pro-resolving mediators, which can be used in the process of developing new anti-inflammatory drugs.
Authors: Sandra Maria Barbalho; Ricardo de Alvares Goulart; Karina Quesada; Marcelo Dib Bechara; Antonely de Cássio Alves de Carvalho Journal: Ann Gastroenterol Date: 2016 Jan-Mar
Authors: Abdulhamied Alfaddagh; Tarec K Elajami; Hasan Ashfaque; Mohamad Saleh; Bruce R Bistrian; Francine K Welty Journal: J Am Heart Assoc Date: 2017-12-15 Impact factor: 5.501
Authors: Diana Lopes; Tânia Melo; Joana Meneses; Maria H Abreu; Rui Pereira; Pedro Domingues; Ana I Lillebø; Ricardo Calado; M Rosário Domingues Journal: Mar Drugs Date: 2019-09-13 Impact factor: 5.118